Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells

Veterinary and Comparative Oncology

Volumn 10, Issue 1, 2012, Pages 44-56

  Hafeman, S D ^a   Varland, D ^a   Dow, S W ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Cancer; Chemotherapy; Dog; Immune; Macrophage

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BISPHOSPHONIC ACID DERIVATIVE; DOXORUBICIN; VINCRISTINE;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; HISTIOCYTIC SARCOMA; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DIPHOSPHONATES; DOG DISEASES; DOGS; DOXORUBICIN; HISTIOCYTIC SARCOMA; VINCRISTINE;

CANIS FAMILIARIS;

EID: 84857034891     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00274.x     Document Type: Article

References (64)

1. Affolter VK and Moore PF. Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. American Journal of Dermatopathology 2000; 22: 40-48.
2. MacEwen EG and Withrow SJ. Small Animal Clinical Oncology. Philadelphia, PA, Saunders Co, 1996.
3. Fulmer AK and Mauldin GE. Canine histiocytic neoplasia: an overview. Canadian Veterinary Journal 2007; 8: 1041-1043 and 1046-1050.
4. Affolter VK and Moore PF. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Veterinary Pathology 2002; 39: 74-83.
5. Moore PF, Affolter VK and Vernau W. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Veterinary Pathology 2006; 43: 632-645.
6. Wellman ML, Krakowka S, Jacobs RM and Kociba GJ. A macrophage-monocyte cell line from a dog with malignant histiocytosis. In Vitro Cellular and Developmental Biology: Journal of the Tissue Culture Association 1988; 24: 223-229.
7. Fidel J, Schiller I, Hauser B, Jausi Y, Rohrer-Bley C, Roos M and Kaser-Hotz B. Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998-March 2005). Veterinary and Comparative Oncology 2006; 4: 63-74.
8. Moore PF and Rosin A. Malignant histiocytosis of Bernese mountain dogs. Veterinary Pathology 1986; 23: 1-10.
9. Rossi S, Gelain ME and Comazzi S. Disseminated histiocytic sarcoma with peripheral blood involvement in a Bernese mountain dog. Veterinary Clinical Pathology 2009; 38: 126-130.
10. Skorupski KA, Rodriguez CO, Krick EL, Clifford CA, Ward R and Kent MS. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. Veterinary and Comparative Oncology 2009; 7: 139-144.
11. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, LeBlanc AK, Sabhlok A, Mauldin EA, Shofer FS, Couto CG and Sorenmo KU. CCNU for the treatment of dogs with histiocytic sarcoma. Journal of Veterinary Internal Medicine/American College of Veterinary Internal Medicine 2007; 21: 121-126.
12. Zavodovskaya R, Liao AT, Jones CL, Yip B, Chien MB, Moore PF and London CA. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. American Journal of Veterinary Research 2006; 67: 633-641.
13. Rosin A, Moore P and Dubielzig R. Malignant histiocytosis in Bernese Mountain dogs. Journal of the American Veterinary Medical Association 1986; 188: 1041-1045.
14. Schultz RM, Puchalski SM, Kent M and Moore PF. Skeletal lesions of histiocytic sarcoma in nineteen dogs. Veterinary Radiology and Ultrasound 2007; 48: 539-543.
15. Bucsky P and Egeler RM. Malignant histiocytic disorders in children. Clinical and therapeutic approaches with a nosologic discussion. Hematology/Oncology Clinics of North America 1998; 12: 465-471.
16. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH and Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999; 85: 2278-2290.
17. Ladisch S and Gadner H. Treatment of langerhans cell histiocytosis - evolution and current approaches. British Journal of Cancer 1994; 70(Suppl. XXIII): s41-s46.
18. Egeler R, de Kraker J and Voǔte PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Medical and Pediatric Oncology 2006; 21: 265-270.
19. Montella L, Merola C, Merola G, Petillo L and Palmieri G. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. Journal of Bone and Mineral Metabolism 2009; 27: 110-113.
20. Cecchini MG, Felix R, Fleisch H and Cooper PH. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 1987; 2: 135-142.
21. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 1995; 10: 1478-1487.
22. Monkkonen J and Heath TD. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron. Calcified Tissue International 1993; 53: 139-146.
23. Tacke F and Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211: 609-618.
24. Frith JC, Monkkonen J, Blackburn GM, Russell RG and Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 1997; 12: 1358-1367.
25. Frith JC, Monkkonen J, Auriola S, Monkkonen H and Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis and Rheumatism 2001; 44: 2201-2210.
26. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Vaananen HK and Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Molecular Pharmacology 2002; 61: 1255-1262.
27. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R and Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Molecular Pharmacology 1996; 50: 1127-1138.
28. van Rooijen N, Sanders A and van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. Journal of Immunological Methods 1996; 193: 93-99.
29. Van Rooijen N and Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. Journal of Immunological Methods 1994; 174: 83-93.
30. Richards PJ, Williams AS, Goodfellow RM and Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 1999; 38: 818-825.
31. Jordan MB, van Rooijen N, Izui S, Kappler J and Marrack P. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 2003; 101: 594-601.
32. Everhart MB, Han W, Parman KS, Polosukhin VV, Zeng H, Sadikot RT, Li B, Yull FE, Christman JW and Blackwell TS. Intratracheal administration of liposomal clodronate accelerates alveolar macrophage reconstitution following fetal liver transplantation. Journal of Leukocyte Biology 2005; 77: 173-180.
33. Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS and Isturiz MA. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 2000; 96: 2834-2840.
34. Halin S, Rudolfsson SH, Van Rooijen N and Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009; 11: 177-186.
35. Miselis NR, Wu ZJ, Van Rooijen N and Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Molecular Cancer Therapeutics 2008; 7: 788-799.
36. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM and Drew AF. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Research 2007; 67: 5708-5716.
37. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K and Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer 2006; 95: 272-281.
38. Zhang W, Zhu X, Sun H, Xiong Y, Zhuang P, Xu H, Kong L, Wang L, Wu W and Tang Z. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clinical Cancer Research 2010; 16: 3420-3430.
39. Mathes M, Jordan M and Dow S. Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Experimental Hematology 2006; 34: 1393-1402.
40. Hafeman SD, London CA, Elmslie R and Dow SW. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunology and Immunotherapy 2010; 59: 441-452.
41. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
42. Roelofs AJ, Thompson K, Gordon S and Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clinical Cancer Research 2006; 12(20 Pt 2): 6222s-6230s.
43. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J and Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88(12 Suppl.): 2961-2978.
44. Berenson J, Vescio R, Henick K, Nishikubo C, Rettig M, Swift R, Conde F and Von Teichert J. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91: 144-154.
45. Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97(3 Suppl.): 840-847.
46. Selander K, Lehenkari P and Vaananen HK. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcified Tissue International 1994; 55: 368-375.
47. Clezardin P, Fournier P, Boissier S and Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Current Medical Chemistry 2003; 10: 173-180.
48. Clyburn R, Reid P, Evans C, LeXey D and Holen I. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemotherapy and Pharmacology 2010; 65: 969-978.
49. Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman R, Clezardin P and Holen I. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clinical Cancer Research 2008; 14: 4658-4666.
50. Peng H, Sohara Y, Moats R, Nelson M, Groshen S, Ye W, Reynolds P and DeClerck Y. The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts andtumor cell survival and proliferation. Cancer Research 2007; 67: 9346-9355.
51. Tsagozis P, Eriksson F and Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunology and Immunotherapy 2008; 57: 1451-1459.
52. Neville-Webbe HL, Evans CA, Coleman RE and Holen I. Mechanisms of the synergistic interaction of the bisphosphonate zoledronic acid and paclitaxel in breast cancer cells in vitro. Tumor Biology 2006; 27: 92-103.
53. Lorimier L and Fan T. Bone metabolic effects of single-dose zoledronate in healthy dogs. Journal of Veterinary Internal Medicine 2005; 19: 924-927.
54. Twentyman PR and Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. British Journal of Cancer 1987; 56: 279-285.
55. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B and Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1-9.
56. Slinker B. The statistics of synergism. Journal of Molecular and Cellular Cardiology 1998; 30: 723-731.
57. Wittenburg LA, Bisson L, Rose BJ, Korch C and Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemotherapy and Pharmacology 2010; 55: 210-220.
58. Martin-Jimenez T, De Lorimier LP, Fan TM and Freise KJ. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics 2007; 30: 492-495.
59. Lauren L, Osterman T and Karhi T. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacology and Toxicology 1991; 69: 365-368.
60. Villikka K, Perttunen K, Rosnell J, Ikavalko H, Vaho H and Pylkkanen L. The absolute bioavailability of clodronate from two different oral doses. Bone 2002; 31: 418-421.
61. Castle MC, Margileth DA and Oliverio VT. Distribution and excretion of (3H)vincristine in the rat and the dog. Cancer Research 1976; 36: 3684-3689.
62. Nooter K, Boersma A, Oostruml RG, Burger H, Jochemsen AG and Stoterl G. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. British Journal of Cancer 1995; 71: 556-561.
63. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J and Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009; 114: 3625-3628.
64. Gustafson DL and Thamm DH. Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. Journal of Veterinary Internal Medicine 2010; 24: 579-586.